Financial Data and Key Metrics Changes - Total fourth quarter revenue reached $11.3 million, representing a 37% year-over-year growth and a quarterly record, exceeding previous guidance [9][19] - Product revenue increased by 78% in Q4, driven by strong system placements, while consumable revenue grew by 11% [11][19] - Recurring revenue increased by 15% for the full year, accounting for 53% of total revenue, indicating strong utilization of installed systems [11] Business Line Data and Key Metrics Changes - The company placed 16 Growth Direct systems in Q4, a record number, bringing the total to 190 systems globally, with 155 fully validated [9][19] - Service revenue was $2 million in Q4, consistent with guidance, but lower than $3 million in Q4 2024 due to timing of validations [20] Market Data and Key Metrics Changes - The partnership with MilliporeSigma is expected to contribute significantly to system placements in 2026, with ongoing training and demo labs established across Europe and Asia [12][15] - The company is seeing strong demand from both principal manufacturers and CDMOs, with significant orders from Amgen and Samsung Biologics [10][15] Company Strategy and Development Direction - The company aims to accelerate system placements, expand gross margins, innovate new products, and manage cash prudently [13][30] - A new cloud-native software platform is expected to be released in the second half of 2026, enhancing customer experience and providing AI-driven analytics [17][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a full-year 2026 revenue guidance of $37 million to $41 million, with expectations for gross margin expansion to approximately 20% [18][29] - The company anticipates strong tailwinds from increased automation adoption and a focus on data integrity in the pharmaceutical industry [16] Other Important Information - Fourth quarter gross margin was impacted by inventory-related charges, but significant progress was made in reducing product costs and improving manufacturing efficiencies [11][21] - The company ended the year with $39 million in cash and investments, aligning with guidance [24] Q&A Session Summary Question: What is being done to reduce the gap between placed and validated systems? - Management indicated that timing variations affect the validation process and expects to see the gap decrease as they work with customers [32][34] Question: What percentage of placed systems are within CDMOs, and how is that space evolving? - Management noted a strong value proposition for CDMOs and highlighted significant orders from both CDMOs and principal manufacturers [35][37] Question: What are the key drivers for achieving the 20% gross margin target for 2026? - Key drivers include locked-in product cost reductions and expected increases in service revenues as validations progress [41][43] Question: How will the next-gen cloud-native software platform be integrated into devices? - The platform will be a complete rewrite of the application software, providing easier integration and potential future revenue from cloud services [67][68] Question: What moves are being made to drive consumable cost reductions? - The company is working with various vendors to achieve significant cost reductions, which will benefit gross margins in 2026 [72][74]

Rapid Micro Biosystems (NasdaqCM:RPID) Q4 2025 Earnings call March 12, 2026 08:30 AM ET Company ParticipantsAnn-Kate Heller - Senior Vice President of Investor RelationsDan Arias - Managing DirectorMichael Beaulieu - VP of Investor Relations and Corporate CommunicationsRobert Spignesi - CEO and PresidentSean Wirtjes - CFOConference Call ParticipantsBrendan Smith - Tools/Dx AnalystThomas Flaten - Senior Research AnalystOperatorGood day, and thank you for standing by.Welcome to the Rapid Micro Biosystems Q4 a ...

Rapid Micro Biosystems (NasdaqCM:RPID) Q4 2025 Earnings call March 12, 2026 08:30 AM ET Speaker4Good day, and thank you for standing by. Welcome to the Rapid Micro Biosystems fourth quarter and full year 2025 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising yo ...